IIMU Biosciences and Waters Advance AI-Driven Immune Mapping Technology
LONDON, UK, June 24, 2026 IMU Biosciences and Waters Corporation announced a strategic partnership to accelerate the development of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LONDON, UK, June 24, 2026 IMU Biosciences and Waters Corporation announced a strategic partnership to accelerate the development of...
MILFORD, Massachusetts, USA – June 8, 2026 Waters Corporation has introduced its BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and...
MILFORD, Massachusetts, USA – June 3, 2026 Waters Corporation has announced U.S. Food and Drug Administration (FDA) 510(k) clearance...
MILFORD, Mass., April 8, 2026 Waters Corporation has announced U.S. FDA clearance for its Onclarityâ„¢ HPV Self-Collection Kit, enabling...
FRANKLIN LAKES, N.J., Feb. 9, 2026 — Becton, Dickinson and Company (BD) announced the successful completion of the previously...
Milford, Massachusetts, January 20, 2026 — Waters Corporation, a global leader in analytical instruments, separations technologies, and laboratory software,...
